Davenport Downgrades Arena Pharmaceuticals (ARNA) to Neutral; PT Suspended
Tweet Send to a FriendGet Alerts ARNA Hot Sheet
Price: $7.98 -0.25%
Rating Summary:
3 Buy, 8 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
3 Buy, 8 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade ARNA Now!
Davenport downgrades Arena Pharmaceuticals (Nasdaq: ARNA) from Buy to Neutral. $8.50 price target suspended.
To see all the upgrades/downgrades on shares of ARNA, visit our Analyst Ratings page.
Shares are trading at $2.10, down $1.65 (-44.00%) in pre-market.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
To see all the upgrades/downgrades on shares of ARNA, visit our Analyst Ratings page.
Shares are trading at $2.10, down $1.65 (-44.00%) in pre-market.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Macquarie Downgrades Barrick Gold (ABX) to Underperform
- Northland Securities Downgrades Cosi Inc. (COSI) to Market Perform
- Art Pappas Elected to NVCA Board of Directors
Create E-mail Alert Related Categories
DowngradesRelated Entities
Davenport
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
